1121
About us
Contact

Address: Room 301, B5 Floor, BioBay, No. 218 Star Lake Street, Suzhou Industrial Park
Tel.:+86-512-86861680
Fax:+86-512-86860292

About us
Your present location:Home

Aokai Biotech specializes in cellular therapy and regenerative medicine, providing high-standard high-quality products and services for clinical applications of human cells and stem cell bio-processing. Our core technologies include human cells separation, purification, amplification, storage, formulation and transportation. We use GMP and quality control systems that measure up to the highest standards to meet the stringent regulations and requirements of the Chinese Food and Drug Administration (CFDA), the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Aokai Biotech was founded in 2012, seated in BioBay of Suzhou Industrial Park. In December 2013, the 1,000 sqm human cells bio-processing experiment zone including three cGMP cell processing rooms were put into use.
Aokai Biotech is focused on the processing and amplification of primary cells in human autologous cells therapy, such as, musculoskeletal tissue repair, tissue regeneration and cell-based immunotherapy, while providing clinical assessments of human stem cells at the GMP level, as well as training for clinicians.

Profile of China Regenerative Medicine Group     

China Regenerative Medicine International Co., Ltd. is China's first high-tech enterprise specializing in the development, production and sale of tissue engineering and regenerative medicine products. On July 18, 2001, the company was listed in the Hong Kong Stock Exchange (stock code: 8158.HK). After 10 years of unremitting efforts, China Regenerative Medicine has successfully built a platform for the R&D and industrialization technologies of tissue engineering products, having become a leader in the field of regenerative medicine and tissue engineering in China. China Regenerative Medicine Group is headquartered in Hong Kong, with six modern production bases respectively in Xi'an, Shenzhen, Suzhou, Tianjin and Hong Kong.   

At present, China Regenerative Medicine Group had filed more than 140 patents at home and abroad, and registered more than 170 trademarks. The company has undertaken major research projects such as the national "863" and "973" programs, twice presided over the development of industry standards, and (participated in) obtained the ”national Science and Technology Progress Award" and many other awards. In 2014, the Group established cooperation with Oxford University to establish "China Regenerative Medicine and Oxford University R & D Center", which has become the Group's core R & D institution. On October 21, 2015, during President Xi Jinping’s visit to Britain, China Regenerative Medicine Group, as the only company in the life sciences area, signed with CCB International and Oxford University the "strategic agreement on establishing a platform for biomedical research results industrialization”, and became one of the 28 business cooperation results during the visit to the UK.  

China Regenerative Medicine Group’s business involves three major parts: tissue engineering, cells and stem cells, and cosmetics. Among them, the “ActivSkin”,  the only tissue-engineered skin that has living cells in China laid the company’s leading position in the field of tissue engineering and regenerative medicine, which is mainly used to accelerate the skin recovery of burns patients, and greatly reduce the pain of patients. The bioengineering cornea "Acornea” is the world's first bioengineered cornea that has undergone clinical trial and has been put into the market, allowing China to stand in the forefront of the corneal regeneration medicine research field. On December 21, 2015, the world's first "Acornea” transplant surgery achieved success in Qingdao Eye Hospital. Since then, it has been successfully carried out in more than 20 provinces and cities such as Hubei, Henan, Jiangxi, Guangdong, Jiangsu, Zhejiang, Shaanxi, Qinghai, Shanxi, Yunnan, Sichuan and Anhui. The vision of patients who recovered the best has been restored to 1.2. The birth of "Acornea” brings light and hope for four million patients with corneal blindness in the country. Otther tissue engineered products include natural calcined bone repair material "CBB”, acellular fistula repair matrix "Resunin”, autologous cartilage cell transplantation sheets “Ruigushu”, guided tissue regeneration biofilm “Morui”. Based on the group’s scientific research results of cell growth factors derived from the tissue engineering production process, the group has launched biomedical active cosmetics - “AMY", thus entering the anti-aging and beauty care industry. In addition, the company also cooperated with the Swiss company Mila D'OPIZ Group to develop and produce the well known biomedical skincare product "Ascara", and the company is responsible for its overall business in Greater China.  

After having achieved initial success in tissue engineering products and their business in the beauty industry beginning to take shape, China Regenerative Medicine is being actively engaged in another core business in the international scale - the research and development cooperation and industrial layout of "cells and stem cells”. Based on the R & D Center of China Regenerative Medicine and Oxford University in China, and the Gene and Cell Engineering Research Institute, the company has initiated the construction of one-stop all-round cells and stem cells therapy facilities, including China Stem Cell Clinical Applications Centre, Hong Kong International Centre for Regenerative Medicine, Suzhou Aokai Biotech, Tianjin Weikai, Changzhou Yize, which specialize in providing clinical grade cell production and processing services for the clinical applications of human cells and stem cell processing. In collaboration with hospitals, they have established cell processing centers to be engaged in the design, manufacturing and sales of cells processing, proliferation, storage and cultivation equipment.  

On March 19, 2016, the Group officially stationed in Hainan Boao Yuecheng International Medical Tourism Pioneering Zone and established cooperation relationships with University of Oxford, University of Hong Kong, and China Resources Medical Group in Hong Kong to undertake the construction of Hainan Boao "Regenerative Medicine Clinical Medical Center" and "Regenerative Medicine Research Center”. The main task of the “Regenerative Medicine Clinical Medical Center" is to build an eye care center with a focus on corneal disease treatment. They use the world's first bio-engineering cornea "Acornea” to carry out a wide range of surgeries, bringing the hope for corneal blindness patients worldwide to get recovered quickly. The center will become a world-class corneal blindness treatment center with the first-of-its-kine technology and the largest scale in China. The first phase of the project is expected to cover an area of 34 mu with a floor area of 23,000 square meters. The first phase of another project, the Boao Regenerative Medicine Research Center, is planned to cover six major industrialization trial platforms. Based on the clinical oriented researches on regenerative medicine carried out in cooperation with Oxford University and other world-class universities and medical institutions, the center is aimed to apply the research results to clinical practices, so that the advanced regenerative medical technologies at home and abroad will achieve rapid industrialization of the pioneering area. The project is estimated to cover an area of 7.5 mu with a floor area of 5,000 square meters.  

Being stationed in Boao Yuecheng International Medical Tourism Pioneering Zone, China Regenerative Medicine is stepping into a glorious era. Backed by the high-quality tourism resources in Hainan, the sound management system and the ample policy support from the pioneering zone, and relying on their international leading patented technologies in the area of regenerative medicine, as well as the leading R & D team and industrial experience, and a mature industry platform, China Regenerative Medicine is bound to create a global leading platform for the regenerative medicine industry.

Group website: http://www.crmi.cn         http://www.crmi.hk